Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation

Journal of Cellular Biochemistry

Volumn 115, Issue 9, 2014, Pages 1505-1515

  Terada, Naoki ^a   Shiraishi, Takumi ^a   Zeng, Yu ^a   Aw Yong, Koh Meng ^a   Mooney, Steven M ^a   Liu, Zhi ^a   Takahashi, Sayuri ^a   Luo, Jun ^a   Lupold, Shawn E ^a   Kulkarni, Prakash ^a   Getzenberg, Robert H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANDROGEN SENSITIVE; MARKER; PROSTATE CANCER

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); EPIDERMAL GROWTH FACTOR RECEPTOR; JAGGED1; MICRORNA 21; NERVE CELL ADHESION MOLECULE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; SPROUTY PROTEIN; SPROUTY1 PROTEIN; UNCLASSIFIED DRUG; ANDROGEN; CALCIUM BINDING PROTEIN; MEMBRANE PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; PHOSPHOPROTEIN; SERRATE PROTEINS; SIGNAL PEPTIDE; SPRY1 PROTEIN, HUMAN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ANDROGEN INSENSITIVITY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CELL CLONE; CELL INVASION; CELL PROLIFERATION; CELL SIZE; CONTROLLED STUDY; COPY NUMBER VARIATION; CORRELATIONAL STUDY; DNA MICROARRAY; FOLLOW UP; GENE DOSAGE; GENETIC DIFFERENCE; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; ANIMAL; CANCER TRANSPLANTATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION;

ANDROGENS; ANIMALS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA COPY NUMBER VARIATIONS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84904438283     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24805     Document Type: Article

References (49)

1. Amano J, Masuyama N, Hirota Y, Tanaka Y, Igawa Y, Shiokawa R, Okutani T, Miyayama T, Nanami M, Ishigai M,. 2010. Antigen-dependent internalization is related to rapid elimination from plasma of humanized anti-HM1. 24 monoclonal antibody. Drug Metab Dispos 38: 2339-2346.
2. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L,. 2004. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100: 2362-2366.
3. Attard G, Reid AH, Olmos D, de Bono JS,. 2009. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69: 4937-4940.
4. Casci T, Vinos J, Freeman M,. 1999. Sprouty, an intracellular inhibitor of Ras signaling. Cell 96: 655-665.
5. Chen J, Imanaka N, Griffin JD,. 2010. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 102: 351-360.
6. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL,. 1999. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59: 5030-5036.
7. Darimipourain M, Wang S, Ittmann M, Kwabi-Addo B,. 2011. Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer. Prostate Cancer Prostatic Dis 14: 279-285.
8. de Maximy AA, Nakatake Y, Moncada S, Itoh N, Thiery JP, Bellusci S,. 1999. Cloning and expression pattern of a mouse homologue of drosophila sprouty in the mouse embryo. Mech Dev 81: 213-216.
9. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT,. 2003. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54: 249-257.
10. Feldman BJ, Feldman D,. 2001. The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
11. Fritzsche S, Kenzelmann M, Hoffmann MJ, Muller M, Engers R, Grone HJ, Schulz WA,. 2006. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 13: 839-849.
12. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S,. 1994. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864.
13. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM,. 1997. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-4691.
14. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA,. 2007. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13: 7003-7011.
15. Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA,. 1998. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92: 253-263.
16. Hanafusa H, Torii S, Yasunaga T, Nishida E,. 2002. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 4: 850-858.
17. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. 1983. LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809-1818.
18. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. 2009. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69: 16-22.
19. Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E, Ogawa O,. 2006. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells. Mol Endocrinol 20: 3053-3069.
20. Inoue T, Leman ES, Yeater DB, Getzenberg RH,. 2008. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate 68: 1048-1056.
21. Isaacs JT, Coffey DS,. 1981. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070-5075.
22. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G, Ittmann M,. 2004. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 64: 4728-4735.
23. Lassi K, Dawson NA,. 2009. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 21: 260-265.
24. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF,. 1998. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 273: 5939-5947.
25. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS,. 2009. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15: 559-565.
26. Macintosh CA, Stower M, Reid N, Maitland NJ,. 1998. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 58: 23-28.
27. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP,. 2000. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56: 527-532.
28. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA,. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
29. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB,. 2007. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67: 7991-7995.
30. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. 2008. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68: 3584-3590.
31. Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, Levesque E,. 2011. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab 96: E1550-E1557.
32. Pflug BR, Reiter RE, Nelson JB,. 1999. Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate 40: 269-273.
33. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley EL, Jr., 1991. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 49: 645-649.
34. Ranganathan P, Weaver KL, Capobianco AJ,. 2011. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat Rev Cancer 11: 338-351.
35. Reich A, Sapir A, Shilo B,. 1999. Sprouty is a general inhibitor of receptor tyrosine kinase signaling. Development 126: 4139-4147.
36. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE,. 2009. MiR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69: 7165-7169.
37. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC,. 2004. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64: 6854-6857.
38. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ,. 2004. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64: 9209-9216.
39. Shen MM, Abate-Shen C,. 2010. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 24: 1967-2000.
40. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH,. 2011. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 9: 153.
41. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L,. 2011. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res 72: 527-536.
42. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE,. 2010. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16: 1414-1420.
43. Thiery JP,. 2003. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740-746.
44. Tilley WD, Buchanan G, Hickey TE, Bentel JM,. 1996. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2: 277-285.
45. van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH,. 1991. The human prostatic cancer cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 40: 207-214.
46. Wang Z, Li Y, Banerjee S, Sarkar FH,. 2008. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res 28: 3621-3630.
47. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM,. 2009. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461: 495-500.
48. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH,. 2010. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 109: 726-736.
49. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y, Sarkar FH,. 2006. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer 119: 2071-2077.